Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MitoQ trial targets MS fatigue – a new hope for tired patients?

NCT ID NCT04267926

Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether MitoQ, a dietary supplement, can reduce fatigue in people with multiple sclerosis. 45 participants took either 20 mg, 40 mg, or a placebo daily for 12 weeks. Researchers measured changes in fatigue using a standard survey. The goal is to find a safe, simple way to improve daily energy for MS patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MitoQ (mitoquinone)
What this could lead to
If it works, this could offer a new option to help manage fatigue in people with multiple sclerosis.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply to everyone. Fatigue is subjective, and the placebo effect could be strong.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

45 people

The number who actually took part.

Started

Apr 2020

Finished

Mar 2026

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * MS (any clinical subtype) as diagnosed by the 2017 McDonald criteria * EDSS score of 2 to 8 * complaint of fatigue that has been persistent for at least two months * Modified Fatigue Impact Scale (MFIS) score of 38 or greater Exclusion Criteria: * treatment with systemic glucocorticoids in the prior six weeks * Beck Depression Inventory (BDI) \>31 or BDI-FS\>10 (severe depression) * significant MS exacerbation in prior 30 days * previous use of MitoQ or Coenzyme Q10 (CoQ10) within thirty days of screening appointment * other significant health problem that might increase risk of patient experiencing Adverse Events (AEs), e.g.: * active coronary heart disease * liver disease * pulmonary disease * diabetes mellitus * pregnancy or intending to become pregnant or breastfeeding * unable to complete the self-report forms * unable to give informed consent * prisoners * any condition which would make the patient in the opinion of the investigator unsuitable for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatigue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fatigue multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fatigue Multiple sclerosis

Contacts and locations

Locations

  • VA Portland Health Care System, Portland, OR

    Portland, Oregon, 97207-2964, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.